

<h3>Bibliografía</h3>

    <ol>
        <li>Chaireti R, Bremme K. Risk factors, treatment and prevention of venous thromboembolism during pregnancy and postpartum. In: Embolic Diseases-Unusual Therapies and Challenges, Chap 2. Intech Open Science 2017. Disponible en: http://dx.doi.org/10.5772/67709</li>
        <li>James A. Pregnancy, contraception and venous thromboembolism (deep vein thrombosis and pulmonary embolism). Vascular Medicine 2017;22:166-9.</li>
        <li>Chan WS, Rey E, Kent NE on behalf of the VTE in Pregnancy Guideline Working Group. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014;36:527-53.</li> 
        <li>Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353;1167-73.</li>
        <li>Nelson SM, Greer IA. Thrombophilia and the risk for venous thrombo-embolism during pregnancy, delivery and puerperium. Obstet Gynecol Clin N Am 2006;33:413-27.</li>
        <li>James AH. Prevention and management of venous thromboembolism in pregnancy. Am J Med 2007;120:s26-s34.</li>
        <li>Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Br J Haematol 2006;132:171-96.</li>
        <li>Ziakas PD, Poulou LS, Pavlou M, Zintzaras E. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk. European J Obstet Gynecol Reprod Biol 2015;191:106-11.</li> 
        <li>Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl 2): e691S-e736S.</li>
        <li>Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N Engl J Med 2000;343:1439-444.</li>
        <li>Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010;56:1-7.</li>
        <li>Royal College of Obstetricians and Gynaecologists Green-top guideline No. 37a. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium 2015.
        <li>Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thrombo-embolism. J Thromb Thrombolysis 2016:41:92-128.</li>
        <li>Guimicheva B, Czuprynska J, Aya R. The prevention of pregnancy-related venous thromboembolism. Br J Haematol 2015;168:163-74.</li>
        <li>Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1994;332:1330-5.</li>
        <li>Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005;106:401-7.</li>
        <li>Greer IA. Pregnancy complicated by venous thrombosis. N Engl J Med 2015;373:540-7.</li>
        <li>Chan WS, Ray JG, Murray S, Coady GE, Coates G, Ginsberg JS. Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. Arch Intern Med 2002;162:1170-5.</li>
        <li>Royal College of Obstetricians and Gynaecologists Green-top guideline No. 37b. Thromboembolic disease in pregnancy and the puerperium: acute management. 2015. Available from: <a href="https://ww.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37b/" target="_blank">https://ww.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37b/</a></li>
        <li>Chan WS, Spencer FA, Lee AY, Chunilal S, Douketis JD, Marc Rodger, et al. Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging. CMAJ 2013;185: E194-E200.</li>
        <li>Simcox LE, Ormesher L, Tower C, Greer IA. Pulmonary thrombo-embolism in pregnancy: diagnosis and management. Breathe 2015:11:282-9.</li>
        <li>Ridge CA, McDermott S, Freyne BJ, Brennan DJ, Collins CD, Skehan SJ, et al. Pulmonary embolism in pregnancy: comparison of pulmonary CT angi­ography and lung scintigraphy. AJR Am 
J Roentgenol 2009;193:1223-7.</li>
        <li>Khan F, Vaillancourt C, Bourjeily G. Diagnosis and management of deep vein thrombosis in pregnancy. BMJ 2017;357:j2344. DOI: 10.1136/bmj.j2344</li>
        <li>Voke J, Keidan J, Pavord S, Spencer HN, Hunt BJ, on behalf of the British Society of Haematology Obstetric Haematology Group. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational study Br J Haematol 2007;139:545-8.</li>
        <li>McDonell BP, Glennon K, McTiernan A, O’Connor HD, Kirkham C, Kevane B, et al. Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism. J Thromb Thrombolysis 2017;43:105-11.</li>
        <li>Te Raa GD, Ribbert LSM, Snijder RJ, Biesma DH. Treatment options in massive pulmonary embolism during pregnancy; a case-report and review of literature. Thromb Res 2009;124:1-5.
        <li>Harris SA, Velineni R, Davies AH. Inferior vena cava filters in pregnancy: a systematic review. J Vasc Interv Radiol 2016;27:354-60.</li>
        <li>Rattray DD, O´Connell CM, Baskett TF. Acute disseminated intra-vascular coagulation in obstetrics: a tertiary centre population review (1980 to 2009). J Obstet Gynaecol Can 2012;34:341-7.</li>
        <li>Cunningham FG, Nelson DB Disseminated Intravascular Coagulation Syndromes in Obstetrics. Obstet Gynecol 2015;126: 999-1001</li>
        <li>Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol 2015;213:452-63.</li>
        <li>Erez O. Disseminated intravascular coagulation in pregnancy. Clinical phenotypes and diagnostic scores Thromb Res 2017;15 (Suppl.1):S56-S60</li>
        <li>Levi M. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Comitte for Standards in Haematology. Br J Haematol 2009;145:24-33.</li>
        <li>American College of Obstetricians and Gynecologists. Practice Bulletin no. 183: Postpartum Hemorrhage. Obstet Gynecol 2017;130:e168-e186.</li>
        <li>Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007;5:266-73.</li>
        <li>Maegele M, Schochl H, Cohen MJ. An update on the coagulopathy of trauma. Shock 2014;41(Suppl 1):21-5.</li>
        <li>Stafford I, Dildy G, Clark S, Belfort M. Visually estimated and calculated blood loss in vaginal and cesarean delivery. Am J Obstet Gynecol 2008;199:519.e1-7.</li>
        <li>Llau JV, Acosta FJ, Escolar G, Fernández-Mondéjard E, Guasche E, Marco P, et al Documento multidisciplinar de consenso sobre el manejo de la hemorragia masiva (documento HEMOMAS). Medicina Intensiva 2015; 39: 483-504.</li>
        <li>Wikkelso A, Wetterslev J, Moller AM. Thromboelastograph (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2015:8CD007871.</li>
        <li>WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389: 2105-16.</li>
        <li>Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003;1:1371-80.</li>
        <li>Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001;85: 958-65.</li>
        <li>Kujovich JL. Von Willebrand’s disease and menorrhagia: prevalence, diagnosis, and management. Am J Hematol 2005;79:220-8.</li>
        <li>American Society of Hematology. Clinical Practice Guideline on the Evaluation and Management of von Willebrand Disease; 2012.</li>
        <li>Kadir RA, James AH. Reproductive health in women with bleeding disorders. World Federation of Hemophilia (WFH), 2009.</li> 
        <li>American College of Obstetricians and Gynecologists. Committee opinion. Von Willebrand disease in women. Number 451, 2015.</li>
        <li>Kuhl H, Birkhäuser M, Mueck A, Neulen J, Thaler C, Kiesel L, Braendle W. Long-cycle treatment in oral contraception. Ther Umsch 2009;66:101-8.</li>
        <li>Royal College of Obstetricians and Gynaecologists. Green-top guideline No. 40. Venous Thromboembolism and Hormonal Contraception; 2010.</li>
        <li>Martínez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 2007;12:97-106.</li>
        <li>Kemmeren IM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1-7.</li>
        <li>Martínez F, Ramírez I, Pérez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012;17:7-29.</li>
        <li>FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. CHC-CVD final report 111022v2. FDA ; 2011. Available from: <a href="http://www.fda.gov/downloads/Drugs/Drug Safety/UCM277384.pdf" target="_blank">http://www.fda.gov/downloads/Drugs/Drug Safety/UCM277384.pdf</a></li>
        <li>Lidegaard O, Lokkegaard E, Svendsen A, Agger C. Hormonal contraception and the risk of venous thromboembolism: a national follow up study. BMJ 2009;339:b2890.</li>
        <li>Van Hylckama V, Helmerhorst F, Vandenbroucke J, Doggen C, Rosendaal F. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.</li>
        <li>Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and metaanalysis. Obstet Gynecol 2013;122(2 Pt 1):380-9.</li>
        <li>Vinogradova Y, Coupland C, Hippisley J. Use of combined oral contracep-tives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015;350:h2135.</li>
        <li>De Bastos M, Stegeman BH, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contraceptives: venous thrombosis (Review). The Cochrane Collaboration; 2014.</li>
        <li>Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral contraceptives and venous thromboembolism. A Systematic Review and Meta-Analysis. Drug Saf 2012;35:191-205.</li>
        <li>Conferencia de Consenso de la SEC 2011. Actualización en el manejo clínico de la AH, Intrauterina y de Urgencia. Madrid: Grupo editorial Entheos; 2012.</li>
        <li>Wilson P W, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories of American Heart Association. Circulation 1998;97:1837-47.</li>
        <li>Practice Committee of American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thrombo-embolism: a guideline. Fertil Steril 2017;
107:43-51.</li>
        <li>Canonico M, Plu-Bureau G, Lowe G, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31.</li>
        <li>Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population based study. J Thromb Haemost 2010;8:979-86.</li>
        <li>Tremollieres F, Brincat M, Erel CT, Gambacciabi M, Lambrinoudaki I, Moen MH, et al. EMAS position statement: managing menopausal women with a personal or family history of VTE. Maturitas 2011;69:190-3.</li>
        <li>Royal College of Obstetricians and Gynaecologists. Green-top guideline No. 19. Venous thrombo-embolism and hormone 
replacement therapy; 2011.</li>
        <li>American College of Obstetricians and Gynaecologists. Committee Opinion No. 556. Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol 2013;121:887-90.</li> 
        <li>Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008;99:338-42.</li>
        <li>Trifiletti A, Gaudio A, Lasco A, Atteritano M, Scamardi R, Pizzoleo MA, et al. Haemostatic effects of phytoestrogen genistein in postmenopausal women. Thromb Res 2008;123:231-5.</li>
    </ol>